PMID- 30324615
OWN - NLM
STAT- MEDLINE
DCOM- 20190419
LR  - 20211204
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 41
IP  - 12
DP  - 2018 Dec
TI  - Troponin-I levels as a potential prognostic biomarker of sacubitril/valsartan 
      treatment response in heart failure with reduced ejection fraction: Who will 
      benefit most?
PG  - 1548-1554
LID - 10.1002/clc.23099 [doi]
AB  - BACKGROUND: Despite robust data on the benefits of sacubitril/valsartan (LCZ696) 
      in patients with chronic heart failure with reduced ejection fraction (HFrEF), 
      there is no evidence yet on prespecified predictive markers of its efficacy. 
      Hypothesis The objective of this study was to identify potential prognostic 
      factors of LCZ696 treatment response. METHODS: We included 48 symptomatic 
      patients with chronic HFrEF (left ventricular ejection fraction </=35%) and New 
      York Heart Association (NYHA) class II/III: Group A (N = 23) received LCZ696 
      (105 +/- 30 mg twice daily), whereas it was not prescribed in group B (N = 25) 
      according to physician's judgment. Analysis of biochemical parameters, 
      cardiopulmonary exercise testing, and echocardiographic evaluation was performed 
      at baseline and 6 months later. RESULTS: The baseline serum troponin-I levels 
      (TnI) and peak oxygen uptake (VO(2) max) were positively associated with the 
      increase in VO(2) max (DeltaVO(2) max = +14.11%, P < 0.05 vs group B) after 
      sacubitril/valsartan treatment (r = 0.68, P = 0.001 and r = 0.57, P = 0.004, 
      respectively). Positive correlations were reported between DeltaVO(2) max and the 
      improvements in the ratio of early diastolic filling to myocardial tissue 
      velocity (DeltaE/E') and the tricuspid annular peak systolic velocity (DeltaSa) in group 
      A (r = 0.58, P = 0.004 and r = 0.60, P = 0.002, respectively). In multiple 
      regression analysis, DeltaVO(2) max was correlated significantly with TnI (beta = 
      0.35, P = 0.048), DeltaE/E' (beta = 0.36, P = 0.031) and DeltaSa (beta = 0.37, P = 
      0.035). CONCLUSIONS: TnI levels may be an independent predictive marker of 
      sacubitril/valsartan efficacy in HFrEF.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Nakou, Eleni S
AU  - Nakou ES
AUID- ORCID: 0000-0003-1921-8117
AD  - Department of Cardiology, Heraklion University Hospital, University of Crete, 
      Crete, Greece.
FAU - Marketou, Maria E
AU  - Marketou ME
AUID- ORCID: 0000-0003-1888-3430
AD  - Department of Cardiology, Heraklion University Hospital, University of Crete, 
      Crete, Greece.
FAU - Chlouverakis, Gregory I
AU  - Chlouverakis GI
AD  - Department of Biostatistics, School of Medicine, University of Crete, Crete, 
      Greece.
FAU - Patrianakos, Alexandros P
AU  - Patrianakos AP
AD  - Department of Cardiology, Heraklion University Hospital, University of Crete, 
      Crete, Greece.
FAU - Vardas, Panos E
AU  - Vardas PE
AD  - Department of Cardiology, Heraklion University Hospital, University of Crete, 
      Crete, Greece.
FAU - Parthenakis, Fragiskos I
AU  - Parthenakis FI
AD  - Department of Cardiology, Heraklion University Hospital, University of Crete, 
      Crete, Greece.
LA  - eng
PT  - Journal Article
DEP - 20181124
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Aminobutyrates)
RN  - 0 (Biomarkers)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Tetrazoles)
RN  - 0 (Troponin I)
RN  - 80M03YXJ7I (Valsartan)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
MH  - Aged
MH  - Aminobutyrates/*therapeutic use
MH  - Biomarkers/blood
MH  - Biphenyl Compounds
MH  - Drug Combinations
MH  - Echocardiography
MH  - Exercise Test
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*blood/drug therapy/physiopathology
MH  - Heart Ventricles/*diagnostic imaging/physiopathology
MH  - Humans
MH  - Male
MH  - Prognosis
MH  - Prospective Studies
MH  - Stroke Volume/*physiology
MH  - Tetrazoles/*therapeutic use
MH  - Troponin I/*blood
MH  - Valsartan
MH  - Ventricular Function, Left/*physiology
PMC - PMC6489982
OTO - NOTNLM
OT  - cardiopulmonary exercise
OT  - heart failure
OT  - predictive biomarkers
OT  - sacubitril/valsartan
COIS- None.
EDAT- 2018/10/17 06:00
MHDA- 2019/04/20 06:00
PMCR- 2018/11/24
CRDT- 2018/10/17 06:00
PHST- 2018/04/04 00:00 [received]
PHST- 2018/09/29 00:00 [revised]
PHST- 2018/10/10 00:00 [accepted]
PHST- 2018/10/17 06:00 [pubmed]
PHST- 2019/04/20 06:00 [medline]
PHST- 2018/10/17 06:00 [entrez]
PHST- 2018/11/24 00:00 [pmc-release]
AID - CLC23099 [pii]
AID - 10.1002/clc.23099 [doi]
PST - ppublish
SO  - Clin Cardiol. 2018 Dec;41(12):1548-1554. doi: 10.1002/clc.23099. Epub 2018 Nov 
      24.